GlassScriptPhysician profile
Nicholas P Thornton
NPI 1831130731
$7,044.70
in general payments reported to CMS, 2019-2025
43 companies · $1,161 in 2025
The $1,161 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $973 · 2020: $742 · 2021: $859 · 2022: $980 · 2023: $952 · 2024: $1,378 · 2025: $1,161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,491.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,491.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,331.56 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $618.53 | 2019-2025 | |
| Abbvie INC. | $570.65 | 2021-2025 | Vraylar, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $566.49 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $469.48 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $451.77 | 2019-2025 | Shingrix, Pediarix, Bexsero |
| Amgen INC. | $341.17 | 2019-2025 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $291.77 | 2019-2024 | Zepbound, Jardiance, Mounjaro |
| Amarin Pharma, INC. | $277.27 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $181.30 | 2019-2023 | Xarelto |
| Sanofi-Aventis U.S. LLC | $159.35 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $145.08 | 2022-2023 | Rexulti |
| Merck Sharp & Dohme LLC | $139.99 | 2020-2024 | Vaxneuvance, Pedvaxhib, Gardasil 9 |
| Biohaven Pharmaceutical Holding Company LTD. | $134.03 | 2022 | |
| Xeris Pharmaceuticals, INC. | $127.94 | 2023-2025 | Gvoke Hypopen |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Thornton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.